Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 8/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417803 | 0.99 | FDFT1 (0.64) | FDFT1S1PR1S1PR4S1PR5HTR6 | |
| Potassium SCHEMBL417805 | 0.99 | FDFT1 (0.64) | FDFT1S1PR1S1PR4S1PR5HTR6 | |
| SCHEMBL8623185 | 0.88 | FDFT1 (0.50) | FDFT1S1PR1S1PR4S1PR3SNCA | |
| SCHEMBL10066424 | 0.83 | FDFT1 (0.63) | FDFT1S1PR1S1PR4S1PR3S1PR2 | |
| Potassium SCHEMBL418042 | 0.82 | FDFT1 (0.62) | FDFT1S1PR1S1PR4S1PR3S1PR2 | |
| SCHEMBL418040 | 0.82 | FDFT1 (0.62) | FDFT1S1PR1S1PR4S1PR3S1PR2 | |
| SCHEMBL8621508 | 0.81 | FDFT1 (0.49) | FDFT1S1PR1S1PR4S1PR3S1PR2 | |
| SCHEMBL8619815 | 0.80 | FDFT1 (0.67) | FDFT1 | |
| SCHEMBL8621227 | 0.80 | FDFT1 (0.67) | FDFT1 | |
| SCHEMBL1538945 | 0.80 | FDFT1 (0.67) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-8778913-B2 | Antimicrobial compositions for treating microbial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) | 2014-06-05 | — | — | US | disclosed |
| US-8148352-B2 | Antimicrobial therapy for bacterial infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2007133712-A2 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-22 | — | — | WO | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306021-A1 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS | SERPINB1, CUTA, SRRT | FDFT1 260/4885S1PR1 3410/4885S1PR4 3106/4885 |
| US-20140154302-A1 | ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | MPO, CUTA, STING1 | FDFT1 368/4885S1PR1 3061/4885S1PR4 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.